You have 9 free searches left this month | for more free features.

amivantamab

Showing 1 - 21 of 21

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC Trial in Houston (Amivantamab, Tepotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

NSCLC Trial (Amivantamab, Lazertinib, Doxycycline)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Amivantamab
  • +6 more
  • (no location specified)
Nov 7, 2023

NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 24, 2023

NSCLC Trial in Korea, Republic of, Malaysia, United States (Cetrelimab, Amivantamab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Fairfax, Virginia
  • +3 more
Jun 16, 2023

Salivary Gland Cancer Trial in Cincinnati (Amivantamab)

Recruiting
  • Salivary Gland Cancer
  • Amivantamab
  • Cincinnati, Ohio
    University of Cincinnati Medical Center
Aug 5, 2022

Stomach Tumors, Esophageal Tumors Trial in Japan (Amivantamab)

Recruiting
  • Stomach Neoplasms
  • Esophageal Neoplasms
  • Amivantamab
  • Chuo-Ku, Japan
  • +10 more
Jan 27, 2023

Esophagogastric Cancer Trial in United States (Amivantamab)

Recruiting
  • Esophagogastric Cancer
  • Amivantamab
  • Boston, Massachusetts
  • +7 more
Oct 24, 2022

NSCLC Trial in Worldwide (Dexamethasone, Montelukast, Methotrexate)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Fountain Valley, California
  • +17 more
Jan 31, 2023

Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer Trial in United States (Amivantamab, Lazertinib)

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Recurrent Non Small Cell Lung Cancer
  • Basking Ridge, New Jersey
  • +6 more
Aug 1, 2022

Carcinoma, Hepatocellular Trial in China (Amivantamab)

Recruiting
  • Carcinoma, Hepatocellular
  • Amivantamab
  • Beijing, China
  • +15 more
Jan 27, 2023

Non Small Cell Lung Cancer Trial in Worldwide (Amivantamab, Lazertinib, Zirabev)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Amivantamab
  • +2 more
  • Angers, France
  • +30 more
Oct 31, 2022

Metastatic NSCLC Trial (Amivantamab)

Approved for marketing
  • Metastatic Non-Small Cell Lung Cancer
  • Amivantamab
  • (no location specified)
Jun 28, 2021

NSCLC Trial in Worldwide (Capmatinib, Amivantamab)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Orange, California
  • +40 more
Aug 3, 2022

Carcinoma, Non-small-Cell Lung Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)

Not yet recruiting
  • Carcinoma, Non-small-Cell Lung
  • Amivantamab
  • +3 more
  • Westwood, Kansas
  • +47 more
Aug 17, 2022

Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer Trial in Huntersville (FT536, Cyclophosphamide, Fludarabine)

Recruiting
  • Non Small Cell Lung Cancer
  • +6 more
  • Scottsdale, Arizona
  • +4 more
Dec 27, 2022

Advanced or Metastatic Colorectal Cancer Trial in Worldwide (Amivantamab, Fluorouracil, Leucovorin)

Recruiting
  • Advanced or Metastatic Colorectal Cancer
  • Amivantamab
  • +4 more
  • Birmingham, Alabama
  • +85 more
Jan 27, 2023

Non-Small-Cell Lung Cancer Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)

Recruiting
  • Non-Small-Cell Lung Cancer
  • Amivantamab
  • +3 more
  • Duarte, California
  • +100 more
Jan 31, 2023

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Los Angeles, California
  • +83 more
Jan 31, 2023

NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Amivantamab
  • +2 more
  • Duarte, California
  • +228 more
Jan 31, 2023

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Phoenix, Arizona
  • +303 more
Aug 17, 2022

NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Amivantamab
  • +3 more
  • Goodyear, Arizona
  • +266 more
Aug 17, 2022